- Home
- IAUX vs KROS Comparison
IAUX vs KROS Comparison
Compare IAUX & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAUX
- KROS
- Stock Information
- Founded
- IAUX 2020
- KROS 2015
- Country
- IAUX United States
- KROS United States
- Employees
- IAUX N/A
- KROS N/A
- Industry
- IAUX
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- IAUX
- KROS Health Care
- Exchange
- IAUX Nasdaq
- KROS Nasdaq
- Market Cap
- IAUX 507.4M
- KROS 565.0M
- IPO Year
- IAUX N/A
- KROS 2020
- Fundamental
- Price
- IAUX $0.93
- KROS $15.66
- Analyst Decision
- IAUX Buy
- KROS Buy
- Analyst Count
- IAUX 1
- KROS 14
- Target Price
- IAUX $1.50
- KROS $20.56
- AVG Volume (30 Days)
- IAUX 5.6M
- KROS 430.7K
- Earning Date
- IAUX 11-11-2025
- KROS 11-05-2025
- Dividend Yield
- IAUX N/A
- KROS N/A
- EPS Growth
- IAUX N/A
- KROS N/A
- EPS
- IAUX N/A
- KROS 0.47
- Revenue
- IAUX $76,622,000.00
- KROS $232,844,000.00
- Revenue This Year
- IAUX $79.79
- KROS $5,579.44
- Revenue Next Year
- IAUX $92.04
- KROS N/A
- P/E Ratio
- IAUX N/A
- KROS $33.82
- Revenue Growth
- IAUX 40.21
- KROS 85820.30
- 52 Week Low
- IAUX $0.34
- KROS $9.12
- 52 Week High
- IAUX $1.26
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- IAUX 75.79
- KROS 59.38
- Support Level
- IAUX $0.85
- KROS $15.23
- Resistance Level
- IAUX $0.90
- KROS $15.85
- Average True Range (ATR)
- IAUX 0.04
- KROS 0.52
- MACD
- IAUX 0.01
- KROS 0.01
- Stochastic Oscillator
- IAUX 92.97
- KROS 72.91
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.